SCHOTT Pharma AG & Co. KGaA (XETRA:1SXP.DE)
| Market Cap | 3.76B+21.6% |
| Revenue (ttm) | 1.02B |
| Net Income | 136.22M |
| EPS | 0.90 |
| Shares Out | 150.61M |
| PE Ratio | 27.72 |
| Forward PE | 22.78 |
| Dividend | €0.18(0.72%) |
| Ex-Dividend Date | Feb 4, 2026 |
| Volume | 18,133 |
| Open | 24.95 |
| Previous Close | 25.15 |
| Day's Range | 24.70 - 25.10 |
| 52-Week Range | 12.62 - 26.05 |
| Beta | 0.87 |
| Analysts | none |
| Price Target | 23.68(-5.07%) |
| Earnings Date | Aug 12, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About 1SXP.DE
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$1SXP.DE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in 1SXP.DE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by 1SXP.DE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
1SXP.DE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New 1SXP.DE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to 1SXP.DE from public contracts
Source: USAspending.gov
1SXP.DE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from 1SXP.DE’s recent data — informational, not investment advice